Drugs / GRAN®
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04174599 Comparator | Apr 2018 → Jan 2019 | breast cancer, neutropenia | EVIVE Biotechnology | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GRAN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04174599 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®)” NCT04174599 ↗ |